title: Effect of antiglaucoma agents on postoperative intraocular pressure after cataract surgery with Viscoat.
abstract: OBJECTIVE
  To compare the effectiveness of brinzolamide 1%, brimonidine 0.2%, acetazolamide 250 mg, intracameral acetylcholine, and timolol 0.5% in preventing intraocular pressure (IOP) peaks during the early period after phacoemulsification in which sodium chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat) was used as the ophthalmic viscosurgical device (OVD).
  
  
  METHODS
  Department of Ophthalmology, Baskent University Medical Faculty, Ankara, Turkey.
  
  
  METHODS
  This prospective randomized study comprised 185 eyes of 185 patients with uncomplicated cataract scheduled for phacoemulsification using Viscoat as the OVD. Patients were randomly assigned to 1 of 6 groups: postoperative application of topical brinzolamide 1%, brimonidine 0.2%, oral acetazolamide 250 mg, intracameral acetylcholine, timolol 0.5%, or no ocular hypotensive agent (control group). The IOP was measured at baseline (preoperatively) as well as 6 hours, 20 to 24 hours, and 1 week after surgery.
  
  
  RESULTS
  The mean preoperative IOP values were not significantly different between the groups. Six hours and 20 to 24 hours postoperatively, the mean IOP was significantly lower in all groups receiving an ocular hypotensive agent than in the control group (P<.01). Six hours after surgery, the mean IOP significantly increased in all groups but was higher in the control group. At 20 to 24 hours, the mean IOP decreased significantly in all ocular hypotensive agent groups but remained significantly high in the control group. One week after surgery, there were no significant differences between the groups.
  
  
  CONCLUSIONS
  Brinzolamide, brimonidine, acetazolamide, intracameral acetylcholine, and timolol had similar effects in reducing IOP increases after phacoemulsification performed using Viscoat.
authors.affiliation: Department of Ophthalmology, Baskent University School of Medicine, Ankara, Turkey. borazan74@hotmail.com
authors.forename: Mehmet
authors.initials: M
authors.lastname: Borazan
authors.forename: Aylin
authors.initials: A
authors.lastname: Karalezli
authors.forename: Ahmet
authors.initials: A
authors.lastname: Akman
authors.forename: Yonca Aydin
authors.initials: YA
authors.lastname: Akova
mesh_terms: D000086:Acetazolamide / Q000008:administration & dosage; D000109:Acetylcholine / Q000008:administration & dosage; D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D000068438:Brimonidine Tartrate; D002807:Chondroitin / Q000627:therapeutic use*; D002809:Chondroitin Sulfates; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D007429:Intraocular Pressure / Q000187:drug effects*; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000517:prevention & control*; D018918:Phacoemulsification; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011810:Quinoxalines / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage; D013843:Thiazines / Q000008:administration & dosage; D013999:Timolol / Q000008:administration & dosage; D014065:Tonometry, Ocular
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D011810:Quinoxalines; D013449:Sulfonamides; D013843:Thiazines; C501944:chondroitin sulfate, sodium hyaluronate drug combination; D000068438:Brimonidine Tartrate; D013999:Timolol; D006820:Hyaluronic Acid; D002807:Chondroitin; D002809:Chondroitin Sulfates; C111827:brinzolamide; D000109:Acetylcholine; D000086:Acetazolamide